ANGI walks into its May 6 earnings report carrying one of the heavier short burdens in its peer group — yet the bears have been quietly retreating over the past month. Short interest now covers roughly 20.7% of the free float, down from a peak above 23% in early April when macro volatility was at its worst. That pullback of around 270 basis points in six weeks suggests some conviction was taken off the table as the stock recovered. The borrow market tells the same story: availability is ample, cost to borrow is a negligible 0.52% APR, and nothing in the lending data points to a squeeze in the making.
Options positioning, by contrast, is structurally defensive — but not unusually so relative to recent history. The put/call ratio is running at 2.18, barely above its 20-day average of 2.15, with a z-score near zero. That elevated baseline PCR simply reflects a market where hedging demand for ANGI has been persistently high; there is no fresh pre-earnings panic in the options market. Price action over the past month has been modestly constructive — the stock added 8% over the last 30 days to close at $7.41, though it slipped fractionally on the week.
The fundamental debate is stark. Bulls point to Q1 2025 revenue coming in $7 million ahead of expectations and a tight relationship between that revenue beat and EBITDA improvement — an argument that the company's efficiency drive is working even as top-line scale has compressed. The EV/EBITDA multiple has been drifting lower, now at roughly 3.5x, which at face value looks cheap. Bears counter that revenue for 2025 was forecast to land just over $1 billion — around half the company's historical peak — and that management's deliberate pullback from third-party volume has permanently reset the growth ceiling. The EPS momentum score for the past 90 days ranks in just the 8th percentile, reflecting a steady stream of downward estimate revisions. Analyst targets published in February — the most recent available — cluster between $12 and $17, well above the current price, but all carry a history of successive cuts since mid-2025. Note that the consensus price target of around $14 is dated to February 2026 and may not fully reflect conditions since the February earnings report.
The last earnings print is the sharpest piece of context heading in. When ANGI reported Q4 results in February, the stock fell 28% on the day and extended to a 32% loss over the following five trading sessions — the market's verdict on guidance being considerably harsher than the headline beat. With short interest still elevated at one-fifth of float and the stock having recovered some ground since that shock, the May 6 report will test whether management can credibly frame the revenue trajectory as stabilisation rather than continued erosion.
See the live data behind this article on ORTEX.
Open ANGI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
